apatinib

Overview

Apatinib is an oral small-molecule inhibitor selectively targeting VEGFR2 (KDR). It has demonstrated anti-angiogenic activity and has been investigated in HCC and NPC, including in combination with immune checkpoint inhibitors.

Evidence in the corpus

• Cited among VEGFR2-targeting anti-angiogenic agents under investigation in HCC PMID:24798001.
• Apatinib + camrelizumab in R/M NPC (NCT04586088, n=58): ORR 65.5%; median PFS 10.4 mo; grade ≥3 TRAE 58.6%; post-platinum ICI-naïve cohort ORR 65%; ICI-refractory ORR 43.3% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• HCC
• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.